Persistent Asset Partners’s Nektar Therapeutics NKTR Stock Holding History
Bought
Maintained
Sold
Other funds holding NKTR
Persistent Asset Partners's NKTR Position: Q3 2026 in Review
Persistent Asset Partners reduced its Nektar Therapeutics (NKTR) stake by 59% in Q3 2026, selling an estimated $312K and leaving 3,040 shares worth $184K. The position accounts for 0.05% of the portfolio, ranked #215.
Persistent Asset Partners first reported a position in NKTR in Q4 2024 and has held it in 5 quarters since. The position peaked at $983K in Q3 2025. 243 funds tracked by Wall St. Rank hold NKTR as of Q3 2026.
- Persistent Asset Partners held 3,040 shares of Nektar Therapeutics worth $184K as of Q3 2026.
- Persistent Asset Partners sold 4,441 Nektar Therapeutics shares in Q3 2026, an estimated $312K.
- Nektar Therapeutics made up 0.05% of Persistent Asset Partners's portfolio in Q3 2026, its #215 holding.
- Persistent Asset Partners first reported a position in Nektar Therapeutics in Q4 2024 and has held it in 5 quarters since.
- Persistent Asset Partners's Nektar Therapeutics position peaked at $983K in Q3 2025.
- 243 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2026.
Based on Persistent Asset Partners's 13F filing for Q3 2026, filed 13 Nov 2026.